S61 Epidemiology of Pancreatic Cancer in Africa: A Systematic Review

Pearlstein, Ethan F.; Tazinkeng, Nkengeh N.; Sawyer, Kelsey; Chukwudike, Evaristus S.; Bains, Kanwal; Asante, Comfort; Sundi, Pharidah Rajan Ibrahim Omar; Chishinga, Nathaniel; Asombang, Akwi W.

doi:10.14309/01.ajg.0000772224.74784.af

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There exists a disparity in pancreatic cancer publication volume, with a majority of studies from two countries, Egypt and Nigeria. Further research is needed to determine country-level factors that may account for this disparity [2].…”

Section: Pancreatic Adenocarcinomamentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic potential of chrysin nanoparticle-mediation inhibition of succinate dehydrogenase and ubiquinone oxidoreductase in pancreatic and lung adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

Pancreatic adenocarcinoma (PDAC) and lung cancer are expected to represent the most common cancer types worldwide until 2030. Under typical conditions, mitochondria provide the bulk of the energy needed to sustain cell life. For that inhibition of mitochondrial complex ΙΙ (CΙΙ) and ubiquinone oxidoreductase with natural treatments may represent a promising cancer treatment option. A naturally occurring flavonoid with biological anti-cancer effects is chyrsin. Due to their improved bioavailability, penetrative power, and efficacy, chitosan–chrysin nano-formulations (CCNPs) are being used in medicine with increasing frequency. Chitosan (cs) is also regarded as a highly versatile and adaptable polymer. The cationic properties of Cs, together with its biodegradability, high adsorption capacity, biocompatibility, effect on permeability, ability to form films, and adhesive properties, are advantages. In addition, Cs is thought to be both safe and economical. CCNPs may indeed be therapeutic candidates in the treatment of pancreatic adenocarcinoma (PDAC) and lung cancer by blocking succinate ubiquinone oxidoreductase.

show abstract

Section: Pancreatic Adenocarcinomamentioning

confidence: 99%

“…Epidemiological measures of pancreatic cancer, including incidence, prevalence, and mortality, vary widely throughout the African continent. Gender was not specified in 1188 patients with 355,317 new cases predicted before 2040 [2]. In Egypt, lung cancer (LC) represents approximately 4.6% of all cancers in both sexes.…”

Section: Introductionmentioning

confidence: 99%